What are the typical findings of alpha‑fetoprotein (AFP), lactate dehydrogenase (LDH), and beta‑human chorionic gonadotropin (β‑hCG) levels in testicular tumors?

Tumor Marker Patterns in Testicular Tumors

In testicular germ cell tumors, AFP is elevated in nonseminomatous tumors (particularly yolk sac elements) but never in pure seminoma, β-hCG can be elevated in both seminomas (15-20%) and nonseminomas (10-60% depending on stage), and LDH is elevated across all tumor types but correlates with tumor bulk and advanced disease.

Marker-Specific Patterns

Alpha-Fetoprotein (AFP)

• Never elevated in pure seminoma - this is a critical diagnostic distinction 1
• Elevated in nonseminomatous germ cell tumors (NSGCTs):
  • 10-20% in stage I disease
  • 20-40% in low-volume stage II
  • 40-60% in advanced disease 1
• Always elevated when yolk sac tumor elements are present 2
• Half-life: 5-7 days 1
• Upper limit of normal: 10-15 µg/L 1

Clinical pitfall: If AFP is elevated in a suspected "seminoma," the tumor is actually a mixed germ cell tumor with nonseminomatous components and should be treated as NSGCT 1.

Beta-Human Chorionic Gonadotropin (β-hCG)

• Can be elevated in both seminomas and nonseminomas 1
• Seminoma: 15-20% of patients with advanced disease show elevation 1
• Nonseminoma:
  • 10-20% in stage I
  • 20-30% in low-volume stage II
  • 40% in advanced disease 1
• Always elevated in choriocarcinoma 2
• Half-life: 1.5-3 days (shorter than AFP) 1
• Upper limit of normal: 5-10 U/L 1

Lactate Dehydrogenase (LDH)

• Elevated across all histologic types but is nonspecific 1
• Correlates with tumor bulk and advanced disease:
  • 20% in stage I
  • 26% in stage II
  • 40-78% in stage III disease 1, 3
• Elevated when ≥1.5 times the laboratory-specific upper limit of normal 1
• Prognostic significance: Patients with initially elevated LDH have worse prognosis (mean survival 9.2 months vs 15.5 months in those with normal LDH) 3

Important caveat: LDH has very low specificity - it can be elevated in myocardial infarction, liver disease, muscle damage, hemolysis, and many other non-malignant conditions 1. However, it remains valuable because at least one of the three markers (AFP, β-hCG, or LDH) is elevated in 91% of patients with advanced nonseminomatous disease 2.

Clinical Application Algorithm

For staging and diagnosis 1:

1. Measure all three markers (AFP, β-hCG, LDH) before orchiectomy
2. Remeasure after orchiectomy
3. Measure again before any chemotherapy

For monitoring nonseminoma 1:

• Measure AFP and β-hCG at the start of each chemotherapy cycle
• Measure shortly before retroperitoneal lymph node dissection
• Monitor periodically for relapse detection

For monitoring seminoma 1:

• Only measure post-orchiectomy β-hCG and LDH if they were elevated pre-orchiectomy
• For advanced seminoma treated with chemotherapy: measure β-hCG and AFP to monitor for relapse
• Do not use markers to detect relapse in stage I seminoma

Critical Diagnostic Distinctions

Sustained or rising AFP or β-hCG levels always indicate persistent or recurrent tumor 2. However, a transient increase during the first week of chemotherapy may occur due to tumor lysis and does not indicate progression 1, 4.

The combination of these three markers provides complementary information: when one marker is normal, another may be elevated, maximizing detection sensitivity across different histologic subtypes 2, 3.